Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer.
Bottom Line: Patients with baseline CEA serum levels below the statistical median of 26.8 ng/mL (group I) were compared with patients with higher CEA levels (group II).The cetuximab-based treatment cohort was analyzed for specificity assessment of CEA to predict the anti-vascular endothelial growth factor effect in mCRC.In an independent cohort of 129 patients treated with cetuximab-based therapy, no association of therapeutic response or PFS with CEA serum levels was found.
Affiliation: Clinical Division of Oncology, Department of Medicine I and Comprehensive Cancer Center, Medical University of Vienna, Austria.Show MeSH
Related in: MedlinePlus
Mentions: The DC assessed according to RECIST criteria in bevacizumab-treated patients correlated with CEA serum levels: DC occurred in 71 (84%) of the 85 patients in group I, and in 50 (60%) of the 84 patients in group II (χ2-test, i < 0.005: odds ratio, 0.579; 95% CI, 0.422–0.795; P < 0.001) (Fig. 1).
Affiliation: Clinical Division of Oncology, Department of Medicine I and Comprehensive Cancer Center, Medical University of Vienna, Austria.